

Annex I

**List of the names, pharmaceutical form, strength of the medicinal products,
route of administration, Marketing Authorisation Holders in the Member
States**

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Austria	Merck Sharp & Dohme Ges.m.b.H. Am Euro Platz 2 1120 Wien Austria	Nasonex aquosum - Nasenspray	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Belgium	MSD Belgium BVBA/SPRL Clos du Lynx 5 B-1200 Bruxelles Belgium	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Bulgaria	Merck Sharp and Dohme Bulgaria EOOD 55, Nikola Vapzarov blvd. EXPO 2000, East Wing, Sectors B1 & B2 1407 Sofia Bulgaria	NASONEX	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Croatia	Merck Sharp & Dohme d.o.o. Heinzelova 62a 10 000 Zagreb Croatia	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Czech Republic	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands	NASONEX	50 µg/dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Denmark	Merck Sharp & Dohme BV Waarderweg 39 Postbox 581 2003 PC Haarlem The Netherlands	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Estonia	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Finland	Merck Sharp & Dohme B.V. Box 581 2003 PC Haarlem The Netherlands	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
France	MSD France 34 avenue Léonard de Vinci 92400 Courbevoie France	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Germany	MSD SHARP & DOHME GMBH Lindenplatz 1 85540 Haar Germany	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Greece	Merck Sharp & Dohme S.A. Ag. Dimitriou 63 174 56 Alimos Greece	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Hungary	MSD Pharma Hungary Kft. H-1095 Budapest Lechner Ödön fasor 8. Hungary	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Iceland	Merck Sharp & Dohme B.V. Box 581 2003 PC Haarlem The Netherlands	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Ireland	Merck Sharp & Dohme Ireland (Human Health) Limited Red Oak North South County Business Park Leopardstown Dublin 18 Ireland	Nasonex	50 µg/ actuation	Nasal Spray, Suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Italy	MSD Italia S.r.l. Via Vitorchiano 151 00189 Roma Italy	Nasonex	50 µg/ actuation	Nasal Spray, Suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Italy	Malesci Istituto Farmacobiologico S.p.A Via Lungo l'Ema 7 Bagno a Ripoli (FI) Italy	Rinelon	50 µg/ actuation	Nasal Spray, Suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Latvia	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands	Nasonex 50 mikrogrami/devā deguna aerosols, suspensija	50 µg/dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU/EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Lithuania	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands	Nasonex	50 µg/ dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate (monohydrate) calculated on the anhydrous basis
Luxembourg	MSD Belgium BVBA/SPRL Clos du Lynx 5 B-1200 Bruxelles Belgium	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Malta	Merck Sharp & Dohme Ltd. Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Netherlands	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Norway	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands	Nasonex	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Poland	MSD Polska Sp. z o.o. ul. Chłodna 51 00-867 Warszawa Poland	Nasonex	50 µg/ dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Portugal	Merck Sharp & Dohme, Lda. Quinta da Fonte, 19 Edifício Vasco da Gama 2770-192 Paço de Arcos Portugal	Nasomet	50 µg/ dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Romania	MERCK SHARP & DOHME ROMANIA S.R.L. Bucharest Business Park Șos. București-Ploiești Nr. 1A, Clădirea C1, Etaj 3, Sector 1, București Romania	NASONEX	50 µg/ dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Slovak Republic	Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem P.O. Box 581 2003 PC Haarlem The Netherlands	NASONEX	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
Slovenia	Merck Sharp & Dohme, inovativna zdravila d.o.o. Šmartinska cesta 140 1000 Ljubljana Slovenia	NASONEX	50 µg/ actuation	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Spain	Merck Sharp & Dohme de España, S.A. C/ Josefa Valcárcel, 38 28027 Madrid Spain	NASONEX 50 microgramos suspension para pulverización nasal	50 µg/ actuation	Nasal Spray, Suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Spain	Desarrollos Farmacéuticos y Cosméticos, S.A. C/ Josefa Valcárcel, 38 28027 Madrid Spain	Mometasone MSD 50 microgramos suspensión para pulverización nasal	50 µg/ actuation	Nasal Spray, Suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis
Sweden	Merck Sharp & Dohme B.V. Box 581 2003 PC Haarlem The Netherlands	Nasonex	50 µg/ dose	Nasal spray, suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis

Member State EU / EEA	Marketing authorisation holder	(Invented) Name	Strength	Pharmaceutical form	Route of administration	Content (concentration)
United Kingdom	Merck Sharp & Dohme Ltd Hertford Road Hoddesdon Hertfordshire EN11 9BU United Kingdom	Nasonex	50 µg/ actuation	Nasal Spray, Suspension	Nasal use	0.05% w/w Mometasone furoate calculated on the anhydrous basis